在神经性正静性低血压中,安普雷洛克赛丁与德罗克西多巴相比:比较性综述
Pranvera Hoxhaj1, Shruti Shah2, Veronica E Muyolema Arce3
1Internal Medicine, Scher & Kerenyi MDS, New York, USA.
Cureus
|June 12, 2023
概括
神经性正静性低血压 (nOH) 治疗方法德罗克西多巴和安普雷洛克西丁可以改善帕金森病患者的症状. 这两种药物都显示出好处,但长期的德洛克西多巴疗效需要进一步研究.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 自主性功能障碍 自主性功能障碍
背景情况:
- 神经性正静性低血压 (nOH) 显著影响帕金森病 (PD) 患者,导致残疾和降低生活质量.
- nOH是一种复杂的自主功能障碍,需要有效的治疗策略.
研究的目的:
- 为了比较droxidopa和ampreloxetine在帕金森病患者的nOH治疗中的疗效和安全性.
- 审查关于nOH管理的现有文献,重点关注德洛克西多巴和安普洛克赛丁的随机对照试验.
主要方法:
- 进行了一项混合方法文献综述.
- 包括 10 个随机对照试验 (8 个用于德洛克西多巴, 2 个用于安普雷洛克赛丁).
- 根据研究结果分析和比较药物的疗效和安全性,重点关注OHSA和OHDAS分数.
主要成果:
- 与安慰剂相比,droxidopa和ampreloxetine在nOH症状和日常活动方面均显示出统计学上显著的改善.
- 德罗克西多巴对日常活动产生了增强的影响,并增加了站立系统血压 (BP).
- 阿姆普洛克赛丁维持了静脉血压,在药物停用后,血压下降,这表明药物持续有效.
结论:
- 德洛克西多巴和安普雷洛克西丁在帕金森病患者中为nOH提供了有效的治疗选择.
- 进一步的研究对于确定长期疗效和优化PD中nOH治疗方法至关重要.
相关概念视频
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.4K
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
417
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
417
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Antihypertensive Drugs: Vasodilators
580
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
580
Antihypertensive Drugs: Direct Renin Inhibitors
709
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
709


